Literature DB >> 17912054

Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice.

Mohammad R Jafari1, Somaye Golmohammadi, Fereshteh Ghiasvand, Mohammad R Zarrindast, Bijan Djahanguiri.   

Abstract

Delta9-tetrahydrocannabinol is the active component in cannabis and has long been associated with pain relief. This effect is believed to be mediated through central and peripheral CB1 and peripheral CB2 receptors. We have explored the possible antinociceptive effect of a CB2 receptor agonist, JWH133, using the formalin test in mice. The drug was administered by the intracerebroventricular and intraperitoneal routes. Although no antinociceptive effect was observed after intracerebroventricular administration of JWH133, when the drug was administered by the intraperitoneal route, it produced an analgesic effect. The influence of nicotinic cholinergic receptor modulators, nicotine and mecamylamine, on antinociceptive effect of JWH133 was also studied. Nicotine increased and mecamylamine decreased the antinociceptive effect of JWH133. It is concluded that JWH133-induced analgesia is influenced by nicotinic cholinergic receptor activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912054     DOI: 10.1097/FBP.0b013e3282f00c10

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  9 in total

1.  Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors:  Weisi Fu; Bradley K Taylor
Journal:  Neurosci Lett       Date:  2015-04-03       Impact factor: 3.046

2.  Antinociceptive effects of JWH015 in female and male rats.

Authors:  Rebecca M Craft; Nicholas Z Greene; Alexa A Wakley
Journal:  Behav Pharmacol       Date:  2018-04       Impact factor: 2.293

3.  Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.

Authors:  Sharon Anavi-Goffer; Gemma Baillie; Andrew J Irving; Jürg Gertsch; Iain R Greig; Roger G Pertwee; Ruth A Ross
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 4.  The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Joseph Bryant; Wilfred Ngwa
Journal:  Int J Mol Sci       Date:  2021-08-31       Impact factor: 6.208

5.  Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine.

Authors:  Francisco Navarrete; Marta Rodríguez-Arias; Elena Martín-García; Daniela Navarro; María S García-Gutiérrez; María A Aguilar; Auxiliadora Aracil-Fernández; Pere Berbel; José Miñarro; Rafael Maldonado; Jorge Manzanares
Journal:  Neuropsychopharmacology       Date:  2013-07-02       Impact factor: 7.853

6.  Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain.

Authors:  David Cabañero; Angela Ramírez-López; Eva Drews; Anne Schmöle; David M Otte; Agnieszka Wawrzczak-Bargiela; Hector Huerga Encabo; Sami Kummer; Antonio Ferrer-Montiel; Ryszard Przewlocki; Andreas Zimmer; Rafael Maldonado
Journal:  Elife       Date:  2020-07-20       Impact factor: 8.140

7.  Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats.

Authors:  M D Jhaveri; S J R Elmes; D Richardson; D A Barrett; D A Kendall; R Mason; V Chapman
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

Review 8.  Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.

Authors:  John M McPartland; Geoffrey W Guy; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 9.  Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.

Authors:  Michelle Roche; David P Finn
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.